Cargando…
Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis
BACKGROUND: The management of atrial fibrillation (AF) with oral anticoagulants (OAC) is generally recommended to reduce the risk of stroke. However, the decision to prescribe these medications for patients with AF and dementia remains controversial. METHODS: A systematic review and meta-analysis of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507720/ https://www.ncbi.nlm.nih.gov/pubmed/37731522 http://dx.doi.org/10.3389/fcvm.2023.1265331 |
_version_ | 1785107374117224448 |
---|---|
author | Wang, Dayang Xu, Xiaoqing Han, Xiaowan Xie, Jing Zhou, Hufang Peng, Wenhua Pan, Guozhong |
author_facet | Wang, Dayang Xu, Xiaoqing Han, Xiaowan Xie, Jing Zhou, Hufang Peng, Wenhua Pan, Guozhong |
author_sort | Wang, Dayang |
collection | PubMed |
description | BACKGROUND: The management of atrial fibrillation (AF) with oral anticoagulants (OAC) is generally recommended to reduce the risk of stroke. However, the decision to prescribe these medications for patients with AF and dementia remains controversial. METHODS: A systematic review and meta-analysis of retrospective cohort studies were conducted. The search encompassed PubMed, Cochrane Library, Web of Science, and Embase databases from inception until May 1st, 2023, with language limited to English. Eligible studies included comparisons between exposure to OAC vs. non-OAC in the AF population with dementia or cognitive impairment. Studies that compared the effects of direct oral anticoagulants (DOAC) and vitamin-K antagonists were also included. The primary outcome was all-cause mortality, and the secondary outcomes were ischemic stroke and major bleeding. This study was registered with PROSPERO (No. CRD42023420678). RESULTS: A total of five studies (N = 21,962 patients) met the eligibility criteria and were included in this review. The follow-up duration ranged from 1 to 4 years. Meta-analysis demonstrated that OAC treatment was associated with a lower risk of all-cause mortality in AF patients with dementia with a hazard ratio (HR) of 0.79 and a 95% confidence interval (CI) ranging from 0.68 to 0.92, compared to non-OAC treatment. No statistical differences were observed in the risk of major bleeding (HR = 1.12, 95% CI: 0.88–1.42) or ischemic stroke (HR = 0.77, 95% CI: 0.58–1.00). Three studies reported comparisons between DOAC and warfarin; however, pooled analysis was not performed due to heterogeneity. CONCLUSION: The use of OACs in individuals diagnosed with both AF and dementia holds the potential to reduce all-cause mortality rates, thereby improving the overall clinical prognosis within this specific population. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023420678, PROSPERO identifier, CRD42023420678. |
format | Online Article Text |
id | pubmed-10507720 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105077202023-09-20 Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis Wang, Dayang Xu, Xiaoqing Han, Xiaowan Xie, Jing Zhou, Hufang Peng, Wenhua Pan, Guozhong Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: The management of atrial fibrillation (AF) with oral anticoagulants (OAC) is generally recommended to reduce the risk of stroke. However, the decision to prescribe these medications for patients with AF and dementia remains controversial. METHODS: A systematic review and meta-analysis of retrospective cohort studies were conducted. The search encompassed PubMed, Cochrane Library, Web of Science, and Embase databases from inception until May 1st, 2023, with language limited to English. Eligible studies included comparisons between exposure to OAC vs. non-OAC in the AF population with dementia or cognitive impairment. Studies that compared the effects of direct oral anticoagulants (DOAC) and vitamin-K antagonists were also included. The primary outcome was all-cause mortality, and the secondary outcomes were ischemic stroke and major bleeding. This study was registered with PROSPERO (No. CRD42023420678). RESULTS: A total of five studies (N = 21,962 patients) met the eligibility criteria and were included in this review. The follow-up duration ranged from 1 to 4 years. Meta-analysis demonstrated that OAC treatment was associated with a lower risk of all-cause mortality in AF patients with dementia with a hazard ratio (HR) of 0.79 and a 95% confidence interval (CI) ranging from 0.68 to 0.92, compared to non-OAC treatment. No statistical differences were observed in the risk of major bleeding (HR = 1.12, 95% CI: 0.88–1.42) or ischemic stroke (HR = 0.77, 95% CI: 0.58–1.00). Three studies reported comparisons between DOAC and warfarin; however, pooled analysis was not performed due to heterogeneity. CONCLUSION: The use of OACs in individuals diagnosed with both AF and dementia holds the potential to reduce all-cause mortality rates, thereby improving the overall clinical prognosis within this specific population. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023420678, PROSPERO identifier, CRD42023420678. Frontiers Media S.A. 2023-09-05 /pmc/articles/PMC10507720/ /pubmed/37731522 http://dx.doi.org/10.3389/fcvm.2023.1265331 Text en © 2023 Wang, Xu, Han, Xie, Zhou, Peng and Pan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Wang, Dayang Xu, Xiaoqing Han, Xiaowan Xie, Jing Zhou, Hufang Peng, Wenhua Pan, Guozhong Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis |
title | Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis |
title_full | Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis |
title_fullStr | Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis |
title_full_unstemmed | Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis |
title_short | Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis |
title_sort | clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507720/ https://www.ncbi.nlm.nih.gov/pubmed/37731522 http://dx.doi.org/10.3389/fcvm.2023.1265331 |
work_keys_str_mv | AT wangdayang clinicalbenefitsoforalanticoagulantsinatrialfibrillationpatientswithdementiaasystematicreviewandmetaanalysis AT xuxiaoqing clinicalbenefitsoforalanticoagulantsinatrialfibrillationpatientswithdementiaasystematicreviewandmetaanalysis AT hanxiaowan clinicalbenefitsoforalanticoagulantsinatrialfibrillationpatientswithdementiaasystematicreviewandmetaanalysis AT xiejing clinicalbenefitsoforalanticoagulantsinatrialfibrillationpatientswithdementiaasystematicreviewandmetaanalysis AT zhouhufang clinicalbenefitsoforalanticoagulantsinatrialfibrillationpatientswithdementiaasystematicreviewandmetaanalysis AT pengwenhua clinicalbenefitsoforalanticoagulantsinatrialfibrillationpatientswithdementiaasystematicreviewandmetaanalysis AT panguozhong clinicalbenefitsoforalanticoagulantsinatrialfibrillationpatientswithdementiaasystematicreviewandmetaanalysis |